비교리스트

 카트 문의
시장보고서
상품코드
1655329

세계의 액체생검 시장

Liquid Biopsy
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 194 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 액체생검 시장은 2030년까지 171억 달러에 달할 전망

2024년에 63억 달러로 추정되는 세계의 액체생검 시장은 2030년에는 171억 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 17.9%로 성장할 것으로 예측됩니다. 액체생검 어세이 키트는 이 리포트에서 분석한 부문의 하나이며, CAGR은 18.0%를 기록하며, 분석 기간 종료시에는 128억 달러에 달할 것으로 예측됩니다. 액체생검 기구 분야의 성장률은 분석 기간 중 CAGR 16.6%로 추정됩니다.

미국 시장은 18억 달러, 중국은 CAGR 17.2%로 성장 예측

미국의 액체생검 시장은 2024년에 18억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 26억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 17.2%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 15.6%와 15.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 13.1%로 성장할 것으로 예측됩니다.

세계 액체생검 시장 - 주요 동향 및 촉진요인 요약

액체생검이 암 진단과 치료에 혁명을 일으킬 수 있는 이유는 무엇인가?

액체생검은 비침습적이고 정확하며 실시간으로 암을 감지하고 모니터링할 수 있는 방법을 제공함으로써 암 진단 및 치료 분야에 혁명을 일으키고 있습니다. 샘플을 채취하기 위해 외과적 수술이 필요한 기존 조직 생검과 달리, 액체생검은 혈액 샘플을 분석하여 순환 종양 세포(CTC), 무세포 DNA(cfDNA) 또는 암과 관련된 기타 바이오마커를 검출합니다. 이를 통해 암을 조기에 발견하고, 병의 진행을 모니터링하고, 치료 효과를 평가할 수 있으며, 이 모든 과정을 환자의 불편함을 최소화할 수 있습니다. 액체생검이 종양의 유전적 구성에 대한 종합적인 지식을 제공할 수 있게 됨에 따라 맞춤형 의료에 변화를 가져왔으며, 종양 전문의는 개별 환자의 필요에 따라 보다 효과적으로 치료할 수 있게 되었습니다. 보다 침습적이지 않고 보다 정확한 진단 툴에 대한 수요가 증가함에 따라 액체생검은 종양학에서 가치 있는 툴로 빠르게 받아들여지고 있습니다.

기술의 발전은 어떻게 액체생검 시장을 주도하고 있는가?

기술의 발전은 액체생검의 성장과 채택을 촉진하는 데 중요한 역할을 하고 있으며, 액체생검의 정확성과 접근성, 유용성을 높이는 데 기여하고 있습니다. 차세대 시퀀싱(NGS) 및 디지털 PCR(중합효소연쇄반응) 기술의 혁신은 액체생검의 민감도와 특이성을 향상시켜 혈액내 미량의 암 관련 바이오마커를 검출할 수 있게 해줍니다. 이러한 발전으로 보다 광범위한 유전자 변이를 식별할 수 있게 되어 종양의 생물학적 특성과 치료 반응에 대한 더 깊은 인사이트을 얻을 수 있게 되었습니다. 또한 첨단 생물정보학 툴의 개발로 액체생검 데이터의 분석과 해석이 개선되어 보다 정확하고 맞춤화된 치료 방침을 보다 쉽게 결정할 수 있게 되었습니다. 액체생검 분석의 지속적인 개선은 장기 이식 거부반응 모니터링, 감염성 질환 감지, 태아기 유전적 상태 평가 등 종양학 이외의 분야에도 적용될 수 있는 가능성을 넓히고 있습니다. 이러한 기술 혁신을 통해 액체생검은 정밀의료 분야에서 더욱 강력하고 다용도한 툴로 거듭나고 있습니다.

어떤 시장 동향이 액체생검 수요를 형성하고 있는가?

액체생검에 대한 수요를 형성하는 몇 가지 중요한 시장 동향이 있습니다. 여기에는 맞춤형 의료에 대한 관심 증가, 비침습적 진단 툴의 채택 확대, 종양학 이외의 액체생검 용도 확대 등이 포함됩니다. 맞춤형 의료가 계속 주도하는 가운데, 표적 치료를 위한 상세한 유전자 정보를 제공하는 진단 툴에 대한 요구가 증가하고 있습니다. 액체생검은 종양유전학에 대한 실시간 인사이트을 제공할 수 있으므로 이러한 접근 방식에 있으며, 매우 중요한 자산이 될 수 있습니다. 비침습적 진단 동향도 액체생검에 대한 수요를 촉진하고 있습니다. 환자와 의료진은 기존의 조직 생검을 대체할 수 있는 보다 덜 침습적이고 편안한 방법을 원하고 있습니다. 또한 액체생검은 이식 모니터링, 감염 감지 등 다른 의료 분야에서도 사용될 수 있으며, 시장 기회가 확대되고 있습니다. 임상시험 및 의약품 개발에서 액체생검의 사용 증가는 치료 반응과 질병 진행을 실시간으로 모니터링할 수 있는 귀중한 툴을 제공하므로 성장에 더욱 기여하고 있습니다.

액체생검 시장의 성장 원동력은 무엇인가?

액체생검 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 액체생검은 기존의 생검을 대체할 수 있는 환자 친화적인 진단 방법을 제공하므로 전 세계 암 발생률 증가와 저침습적 진단 방법에 대한 수요 증가가 큰 원동력이 되고 있습니다. 유전체 및 분자진단의 기술 발전은 액체생검의 정확성과 유용성을 향상시켜 임상의와 환자 모두에게 더욱 매력적인 선택이 되고 있습니다. 맞춤형 의료의 도입이 확대되고, 암의 진행과 치료 효과를 실시간으로 모니터링해야 할 필요성이 높아진 것도 시장 확대에 기여하고 있습니다. 또한 이식 모니터링, 산전 검사 등 종양학 이외의 분야로의 적용이 확대되고 있는 것도 새로운 성장 기회를 창출하고 있습니다. 액체생검을 활용한 임상시험과 연구개발 증가는 시장 개척을 더욱 촉진하고 있으며, 이러한 노력은 이 혁신적인 기술의 잠재적 용도를 검증하고 확대하는 데 기여하고 있습니다.

부문

제공(분석 키트, 기기, 서비스);&기술(다유전자 병렬 분석, 단일 유전자 분석);&용도(암, 비암);&최종 용도(참조 실험실, 병원 및 의사 실험실, 학술 및 연구센터, 기타 최종 용도)

조사 대상 기업의 예(총 42사)

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA 25.02.28

Global Liquid Biopsy Market to Reach US$17.1 Billion by 2030

The global market for Liquid Biopsy estimated at US$6.3 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. Liquid Biopsy Assay Kits, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$12.8 Billion by the end of the analysis period. Growth in the Liquid Biopsy Instruments segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 17.2% CAGR

The Liquid Biopsy market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.1% CAGR.

Global Liquid Biopsy Market - Key Trends & Drivers Summarized

Why Is Liquid Biopsy Revolutionizing Cancer Diagnosis and Treatment?

Liquid biopsy is revolutionizing the field of cancer diagnosis and treatment by offering a non-invasive, accurate, and real-time method to detect and monitor cancer. Unlike traditional tissue biopsies, which require surgical procedures to obtain samples, liquid biopsies involve analyzing a blood sample to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), or other biomarkers associated with cancer. This approach allows for the early detection of cancer, monitoring of disease progression, and assessment of treatment efficacy, all with minimal discomfort to the patient. The ability of liquid biopsies to provide comprehensive insights into the genetic makeup of tumors is transforming personalized medicine, enabling oncologists to tailor treatments to individual patients' needs more effectively. As the demand for less invasive, more accurate diagnostic tools grows, liquid biopsy is rapidly gaining acceptance as a valuable tool in oncology.

How Are Technological Advancements Driving the Liquid Biopsy Market?

Technological advancements are playing a crucial role in driving the growth and adoption of liquid biopsy, making it more accurate, accessible, and informative. Innovations in next-generation sequencing (NGS) and digital PCR (Polymerase Chain Reaction) technologies are enhancing the sensitivity and specificity of liquid biopsies, allowing for the detection of minute amounts of cancer-related biomarkers in the blood. These advancements are enabling the identification of a broader range of genetic mutations, providing deeper insights into tumor biology and treatment response. Additionally, the development of advanced bioinformatics tools is improving the analysis and interpretation of liquid biopsy data, facilitating more precise and personalized treatment decisions. The ongoing refinement of liquid biopsy assays is also expanding their application beyond oncology, with potential uses in monitoring organ transplant rejection, detecting infectious diseases, and assessing prenatal genetic conditions. These technological innovations are making liquid biopsy a more powerful and versatile tool in precision medicine.

What Market Trends Are Shaping the Demand for Liquid Biopsy?

Several key market trends are shaping the demand for liquid biopsy, including the increasing emphasis on personalized medicine, the growing adoption of non-invasive diagnostic tools, and the expansion of liquid biopsy applications beyond oncology. As personalized medicine continues to gain traction, there is a growing need for diagnostic tools that can provide detailed genetic information to guide targeted therapies. Liquid biopsy's ability to offer real-time insights into tumor genetics makes it a valuable asset in this approach. The trend towards non-invasive diagnostics is also driving demand for liquid biopsy, as patients and healthcare providers seek less invasive, more comfortable alternatives to traditional tissue biopsies. Additionally, the potential for liquid biopsy to be used in other areas of medicine, such as transplant monitoring and infectious disease detection, is expanding its market opportunities. The increasing use of liquid biopsy in clinical trials and drug development is further contributing to its growth, as it provides a valuable tool for monitoring treatment response and disease progression in real-time.

What Is Driving the Growth in the Liquid Biopsy Market?

The growth in the liquid biopsy market is driven by several factors. The rising incidence of cancer worldwide and the growing demand for less invasive diagnostic methods are major drivers, as liquid biopsy offers a more patient-friendly alternative to traditional biopsies. Technological advancements in genomics and molecular diagnostics are enhancing the accuracy and utility of liquid biopsy, making it a more attractive option for both clinicians and patients. The increasing adoption of personalized medicine and the need for real-time monitoring of cancer progression and treatment response are also contributing to the market's expansion. Additionally, the broadening of liquid biopsy applications beyond oncology, such as in transplant monitoring and prenatal testing, is creating new opportunities for growth. The growing number of clinical trials and research studies utilizing liquid biopsy is further supporting market development, as these efforts continue to validate and expand the potential uses of this innovative technology.

SCOPE OF STUDY:

The report analyzes the Liquid Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Assay Kits, Instruments, Services); Technology (Multi Gene Parallel Analysis, Single Gene Analysis); Application (Cancer, Non-Cancer); End-Use (Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Liquid Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Clinical Applications Propel Growth in the Liquid Biopsy Market
    • Advancements in Circulating Tumor DNA (ctDNA) Technologies Drive Diagnostic Innovations
    • Integration of Liquid Biopsy with Precision Oncology Enhances Treatment Personalization
    • Rising Prevalence of Cancer Worldwide Boosts Demand for Non-Invasive Diagnostic Methods
    • Technological Breakthroughs in Single-Cell Analysis Expand Capabilities of Liquid Biopsy
    • FDA Approvals Accelerate Adoption of Liquid Biopsy Tests in Clinical Settings
    • Collaborations between Biotech Firms and Academic Institutions Fuel Research and Development
    • Growing Investment in Personalized Medicine Spurs Development of Targeted Therapies Using Liquid Biopsy
    • Market Challenges Posed by Sensitivity and Specificity Concerns in Early Cancer Detection
    • Impact of Artificial Intelligence on Enhancing Accuracy and Speed of Liquid Biopsy Analysis
    • Insurance Coverage and Reimbursement Policies Shape the Liquid Biopsy Landscape
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Multi Gene Parallel Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Multi Gene Parallel Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Single Gene Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Non-Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Non-Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Hospitals & Physician Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Academic & Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Academic & Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Liquid Biopsy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of World 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제